You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy

    SBC: AFFIRMED PHARMA, LLC            Topic: NEI

    Abstract Radiation induced keratopathy results in significant ocular surface disease, stem cell deficiency, vision loss, discomfort, and subsequent poor quality of life, affecting up to 23% of patients receiving radiation therapy for head and neck malignancies [1]. Studies have pointed out functional roles of corneal neurons and secretory cells of the lacrimal gland in the etiology of radiation in ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a novel system combining cognitive assessment with PASCALL FDA-cleared intraoperative anesthesia EEG brain monitor to prevent postoperative neurocognitive disorders in aging patients

    SBC: PASCALL Systems, Incorporated            Topic: NIA

    Each day, more than 100,000 patients undergo general anesthesia in the United States. The current practice of general anesthesia is prone to over-sedating patients, either due to the lack of brain monitoring or using brain monitors with inaccurate indices. Over-sedation (at 28% incidence) contributes to perioperative neurocognitive disorders (PNDs) in elderly population (≥65yrs). The cost of PND ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. A Mobile-Delivered Personalized Feedback Intervention for Black Individuals who Engage in Hazardous Drinking

    SBC: HEALTH BEHAVIOR SOLUTIONS INC            Topic: 400

    PROJECT SUMMARY/ABSTRACT Black persons are the second largest racial minority group in the United States (US) and experience striking health disparities, particularly in terms of hazardous drinking and co-occurring elevated anxiety. The co- occurrence of these risk factors contributes to worse physical/mental health outcomes among Black individuals. Few interventions to date have targeted hazardou ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Membrane repair as a therapeutic intervention for treating Becker Muscular Dystrophy

    SBC: MYOFINITY BIOSCIENCES INC            Topic: NIAMS

    PROJECT ABSTRACTThe goal of this combined Phase I/II SBIR project is to accomplish key milestones in commercializing a protein therapeutic for Becker muscular dystrophy (BMD) that will enhance the repair capacity of muscle cell sarcolemmal membranes compromised by mutations in the dystrophin gene that reduce the expression level or function of the dystrophin protein. Many mutations in the dystroph ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. IND-enabling studies for cell therapy in Parkinson's disease

    SBC: NEONEURON LLC            Topic: 105

    Parkinson’s disease (PD) is a progressive neurodegenerative disease that is currently incurable with significant unmet medical needs. In the US, over a million people suffer from this disease with an estimated cost of $27 billion per year. The mainstay of PD management is symptomatic treatment with drugs that increase dopamine in the striatum. However, the utility of these drugs is significantly ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Urine Test for At-Home Monitoring of Blood Phe Levels for PKU

    SBC: CIRCA BIOSCIENCE LLC            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT This project proposes the development of technologies to provide low-cost monitoring of phenylalanine (Phe) levels in the blood by a simple, noninvasive, at-home urine test, in order to enable daily monitoring by individuals with phenylketonuria (PKU). Also known as phenylalanine hydroxylase deficiency, PKU is a rare inborn error of metabolism that occurs in the US at a fr ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Developing Active Stimulation and Monitoring Technologies to Optimize Pain and Nociception Management During Regional Anesthesia, General Anesthesia, and Post-Operative Care

    SBC: PASCALL Systems, Incorporated            Topic: 106

    Project Summary Surgery and acute post-operative pain are major contributors to persistent pain, chronic pain, and opioid dependence. Currently, there are no products on the market in the United States that can be used to monitor surgical nociception. Existing products use indicators that are susceptible to intraoperative influences such as blood loss, anesthetic drugs and antihypertensives. This ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a virtual reality guided acupuncture imagery treatment for Chronic low back pain

    SBC: MASSACHUSETTS NEURO TECHNOLOGY, INC.            Topic: NCCIH

    Project Summary Low back pain (LBP) is one of the most common reasons for physician visits in the USA. A substantial number of chronic LBP (cLBP) patients do not adequately respond to current treatment options. Thus, the development of new treatments for cLBP is urgently needed. The use of imagery to treat illness, including chronic pain, is one of the oldest medical practices. Although still unde ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis

    SBC: GLYCOPATH INC            Topic: 400

    Lupus nephritis (LN), an immune complex-mediated glomerulonephritis, affects up to two-thirds of patients with systemic lupus erythematosus. Despite standard treatment protocols, progression of the most aggressive forms of LN (class III and IV) to end-stage renal failure remains high. Thus, there is a need for biomarkers of therapeutic response that would allow physicians to make better-informed t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis

    SBC: FibroBiologics, LLC            Topic: NHLBI

    Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival of only 3 - 5 years from diagnosis. Although two FDA-approved drugs, pirfenidone and nintedanib, may slow the rate of decline of lung function in some IPF patients, neither drug significantly alters the course of this lethal disease. There is a great need for new drugs with greater efficacy and le ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government